Clinical Study on Tongluo Pingchuan Decoction in the Treatment of Infantile Cough Variant Asthma
[Objective]To investigate the clinical efficacy and possible mechanism of Tongluo Pingchuan Decoction in the treatment of infantile cough variant asthma(CVA).[Methods]Seventy-two patients with CVA were randomized into treatment group(36 cases)and control group(36 cases).Treatment group were treated with Tongluo Pingchuan Decoction while the cases in control group were treated with oral Ambroxol and Montelukast.Then the mitigation of cough symptoms and the changes of immunoglobulin E(IgE),eosinophils(EOS),interleukin-4(IL-4)and interferon-γ(IFN-γ)were observed.[Results]After treatment,the symptom scores were both decreased(P<0.01),and the treatment group was superior to the control group(P<0.01,P<0.05).The efficacy of the treatment group was better than that of the control group(P<0.05),and the onset time of the treatment group was significantly shorter than that of the control group(P<0.05).The level of EOS,IgE,IL-4 and IFN-γ of two groups were improved after treatment(P<0.01),and there was no statistically difference between the two groups(P>0.05).After 3 months of follow-up,the recurrence rate of the two groups was statistically different(P<0.01).[Conclusion]Tongluo Pingchuan Decoction can significantly relieve the cough symptoms of in children with CVA,reduce the recurrence rate,and the possible mechanism may be associated with regulating inflammatory factor levels.
NETL
NSTL
万方数据
